- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- IPO Date
- Aug 3, 2023
Highlights
- EPS (TTM)
- -$1.57
- EBITDA (TTM)
- -$6.93M
- Year Range
- $0.90 - $2.45
- ROA (TTM)
- -256.14%
- ROE (TTM)
- -273.45%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
MIRA Performance Chart
MIRA Pharmaceuticals Inc. Common Stock (MIRA) is down 33.1% since the beginning of the year. At $1 per share, MIRA is trading 58.8% below its 52-week high of $2.
Loading charts...
Returns By Period
MIRA Pharmaceuticals Inc. Common Stock (MIRA) has returned -33.11% so far this year and -26.81% over the past 12 months.
MIRA Pharmaceuticals Inc. Common Stock
- 1D
- -2.88%
- 1M
- -1.94%
- YTD
- -33.11%
- 6M
- -29.86%
- 1Y
- -26.81%
- 3Y*
- —
- 5Y*
- —
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -0.74%
- 1M
- 4.90%
- YTD
- 10.35%
- 6M
- 10.28%
- 1Y
- 26.52%
- 3Y*
- 20.83%
- 5Y*
- 12.30%
- 10Y*
- 13.66%
MIRA Monthly Returns History
Based on dividend-adjusted daily data since Aug 3, 2023, MIRA's average daily return is +0.64%, while the average monthly return is +2.32%. At this rate, an investment would double in approximately 2.5 years.
Historically, 37% of months were positive and 63% were negative. The best month was Jul 2024 with a return of +229.7%, while the worst month was Dec 2023 at -70.4%. The longest winning streak lasted 2 consecutive months, and the longest losing streak was 3 months.
On a daily basis, MIRA closed higher 40% of trading days. The best single day was Jul 22, 2024 with a return of +627.4%, while the worst single day was Jul 23, 2024 at -48.9%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -17.88% | 2.42% | -15.75% | -1.87% | 0.95% | -4.72% | -33.11% | ||||||
| 2025 | 5.26% | -16.67% | -2.00% | 18.37% | 16.38% | -10.37% | 36.36% | -16.97% | -0.73% | 22.79% | -11.38% | 2.03% | 32.46% |
| 2024 | -10.48% | 6.91% | 9.45% | -22.74% | -3.73% | -22.15% | 229.67% | -8.10% | -32.64% | 68.46% | -41.10% | -11.63% | 8.57% |
| 2023 | -15.45% | -25.88% | -58.28% | 82.99% | -70.42% | -85.85% |
Benchmark Metrics
MIRA Pharmaceuticals Inc. Common Stock has an annualized alpha of 258.18%, beta of 1.71, and R2 of 0.00 versus S&P 500 Index. Calculated based on daily prices since August 04, 2023.
- This stock participated in 277.57% of S&P 500 Index downside but only -61.29% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.00 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 258.18%
- Beta
- 1.71
- R²
- 0.00
- Upside Capture
- -61.29%
- Downside Capture
- 277.57%
Return for Risk
Risk / Return Rank
MIRA ranks 27 for risk / return — below 27% of stocks on our site. The returns aren't fully compensating for the risk involved. This isn't necessarily a dealbreaker, but factor it into your decision — especially if you're risk-averse.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for MIRA Pharmaceuticals Inc. Common Stock (MIRA) and compare them to S&P 500 Index.
| MIRA | Benchmark | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | -0.34 | 2.24 | -2.58 |
Sortino ratioReturn per unit of downside risk | -0.04 | 3.07 | -3.11 |
Omega ratioGain probability vs. loss probability | 1.00 | 1.41 | -0.41 |
Calmar ratioReturn relative to maximum drawdown | -0.49 | 2.93 | -3.42 |
Martin ratioReturn relative to average drawdown | -0.79 | 13.52 | -14.31 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the MIRA Pharmaceuticals Inc. Common Stock. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the MIRA Pharmaceuticals Inc. Common Stock was 92.69%, occurring on Jul 9, 2024. The portfolio has not yet recovered.
The current MIRA Pharmaceuticals Inc. Common Stock drawdown is 86.39%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2024 bear market2024 | -92.69%Jul 2024 | 11mo 10d | — | 2y 10moAug 2023 - now |
Drawdown Indicators
| MIRA | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -92.69% | -56.78% | -35.91% |
Max Drawdown (1Y)Largest decline over 1 year | -54.46% | -9.10% | -45.36% |
Max Drawdown (3Y)Largest decline over 3 years | — | -18.90% | — |
Max Drawdown (5Y)Largest decline over 5 years | — | -25.43% | — |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -86.39% | -0.74% | -85.65% |
Average DrawdownAverage peak-to-trough decline | -78.38% | -10.72% | -67.66% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 34.04% | 1.97% | +32.07% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of MIRA Pharmaceuticals Inc. Common Stock over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how MIRA Pharmaceuticals Inc. Common Stock is priced in the market compared to other companies in the Drug Manufacturers - General industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with MIRA
Add MIRA Pharmaceuticals Inc. Common Stock to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with MIRA